We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has BioNTech SE Sponsored (BNTX) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of BioNTech SE Sponsored (BNTX - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
BioNTech SE Sponsored is one of 1122 individual stocks in the Medical sector. Collectively, these companies sit at #15 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. BNTX is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for BNTX's full-year earnings has moved 22.85% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, BNTX has returned 198.11% so far this year. In comparison, Medical companies have returned an average of -8.58%. This means that BioNTech SE Sponsored is performing better than its sector in terms of year-to-date returns.
Looking more specifically, BNTX belongs to the Medical - Biomedical and Genetics industry, a group that includes 511 individual stocks and currently sits at #172 in the Zacks Industry Rank. On average, this group has lost an average of 11.90% so far this year, meaning that BNTX is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to BNTX as it looks to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has BioNTech SE Sponsored (BNTX) Outpaced Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of BioNTech SE Sponsored (BNTX - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
BioNTech SE Sponsored is one of 1122 individual stocks in the Medical sector. Collectively, these companies sit at #15 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. BNTX is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for BNTX's full-year earnings has moved 22.85% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, BNTX has returned 198.11% so far this year. In comparison, Medical companies have returned an average of -8.58%. This means that BioNTech SE Sponsored is performing better than its sector in terms of year-to-date returns.
Looking more specifically, BNTX belongs to the Medical - Biomedical and Genetics industry, a group that includes 511 individual stocks and currently sits at #172 in the Zacks Industry Rank. On average, this group has lost an average of 11.90% so far this year, meaning that BNTX is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to BNTX as it looks to continue its solid performance.